Original Research
Published on 12 Nov 2024
A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib
in Head and Neck Cancer
- 274 views
Original Research
Published on 12 Nov 2024
in Head and Neck Cancer
Original Research
Accepted on 08 Nov 2024
in Head and Neck Cancer
Original Research
Published on 08 Nov 2024
in Head and Neck Cancer
Systematic Review
Accepted on 07 Nov 2024
in Head and Neck Cancer
Systematic Review
Accepted on 06 Nov 2024
in Head and Neck Cancer
Original Research
Published on 06 Nov 2024
in Head and Neck Cancer
Review
Published on 04 Nov 2024
in Head and Neck Cancer
Original Research
Accepted on 01 Nov 2024
in Head and Neck Cancer
Original Research
Published on 01 Nov 2024
in Head and Neck Cancer
Systematic Review
Published on 01 Nov 2024
in Head and Neck Cancer
Original Research
Accepted on 29 Oct 2024
in Head and Neck Cancer
Original Research
Published on 24 Oct 2024
in Head and Neck Cancer
Original Research
Published on 24 Oct 2024
in Head and Neck Cancer
Case Report
Published on 23 Oct 2024
in Head and Neck Cancer
Original Research
Accepted on 22 Oct 2024
in Head and Neck Cancer
Case Report
Accepted on 21 Oct 2024
in Head and Neck Cancer